NCT04868968View on ClinicalTrials.gov

Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)

PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

September 20, 2021

Primary Completion Date

December 13, 2022

Study Completion Date

May 5, 2023

Conditions
Familial Cold Autoinflammatory Syndrome
Interventions
DRUG

DFV890

100 mg of DFV890 film coated tablets twice daily (b.i.d.). for 3 days starting in the morning of Day 1 and 100 mg of DFV890 in the morning on the fourth day.

Trial Locations (3)

72076

Novartis Investigative Site, Tübingen

75970

Novartis Investigative Site, Paris

92093

Novartis Investigative Site, La Jolla

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY